


IPW

TRANSMITTAL FORM



| | |
|---------------------------|-------------------|
| Application Serial Number | 10/737,208 |
| Filing Date | December 16, 2003 |
| First Named Inventor | Gillies |
| Group Art Unit | 1653 |
| Examiner Name | Not yet assigned |
| Attorney Docket No. | LEX-023 |
| Patent No. | Not applicable |
| Issue Date | Not applicable |


ENCLOSURES (check all that apply)

| | | |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form <input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____] <input type="checkbox"/> Petition for Extension of Time <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> Copies of cited references (B1-B107 and C1-C261) <input type="checkbox"/> Check Attached <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above | <input type="checkbox"/> Copy of Notice to File Missing Parts of Application <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program <input type="checkbox"/> Amendment After Allowance <input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate) | <input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in triplicate) <input type="checkbox"/> Status Inquiry <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <input type="checkbox"/> Additional Enclosure(s) (please identify below) |
|--|---|--|

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
 Testa, Hurwitz & Thibault, LLP
 High Street Tower
 125 High Street
 Boston, MA 02110
 Tel. No.: (617) 248-7000
 Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,

 Brian A. Fairchild, Ph.D.
 Attorney for the Applicants
 Testa, Hurwitz & Thibault, LLP
 High Street Tower
 125 High Street
 Boston, MA 02110

Date: August 13, 2004
 Reg. No. 48,645
 Tel. No.: (617) 248-7697
 Fax No.: (617) 248-7100



PATENT
Attorney Docket No. LEX-023

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies *et al.* CONF. NO.: 6855
SERIAL NO.: 10/737,208 GROUP NO.: 1653
FILING DATE: December 16, 2003 EXAMINER: Not yet assigned
TITLE: IMMUNOCYTOKINE SEQUENCES AND USES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with the U.S. Patent and Trademark Office's partial waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. § 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. § 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. § 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. § 1.17(p), namely **\$180.00**, is included herein, or

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. § 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application. Please charge any fee deficiency or credit any overpayment to deposit account 20-0531.


Respectfully submitted,



Brian A. Fairchild, Ph.D.
Attorney for Applicants
Testa, Hurwitz, & Thibault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

August 13, 2004
Reg. No. 48,645
Tel. No.: (617) 248-7697
Fax No.: (617) 248-7100

3090008

| FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO. LEX-023 APPLICANT(S): Gillies <i>et al.</i> SERIAL NO. 10/737,208 CONF. NO. 6855 FILING DATE: December 16, 2003 GROUP: 1653 | | | |
|--|-----|--------------------|----------|--|-------|--------------|-------------------------------|
|  U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| | A1 | 07/348,237 | 5/5/89 | Rosenblum et al. | | | |
| | A2 | 4,196,265 | 4/1/80 | Koprowski et al. | | | |
| | A3 | 4,469,797 | 9/4/84 | Albarella | | | |
| | A4 | 4,676,980 | 6/30/87 | Segal et al. | | | |
| | A5 | 4,703,008 | 10/27/87 | Lin | | | |
| | A6 | 4,816,567 | 3/28/89 | Cabilly et al. | | | |
| | A7 | 4,946,778 | 8/7/90 | Ladner et al. | | | |
| | A8 | 5,019,368 | 5/28/91 | Epstein et al. | | | |
| | A9 | 5,073,627 | 12/17/91 | Curtis et al. | | | |
| | A10 | 5,114,711 | 5/19/92 | Bell et al. | | | |
| | A11 | 5,116,964 | 5/26/92 | Capon et al. | | | |
| | A12 | 5,199,942 | 4/6/93 | Gillis | | | |
| | A13 | 5,225,538 | 7/6/93 | Capon et al. | | | |
| | A14 | 5,225,539 | 7/6/93 | Winter | | | |
| | A15 | 5,258,498 | 11/2/93 | Huston et al. | | | |
| | A16 | 5,314,995 | 5/24/94 | Fell, Jr. et al. | | | |
| | A17 | 5,349,053 | 9/20/94 | Landolfi | | | |
| | A18 | 5,359,035 | 10/25/94 | Habermann | | | |
| | A19 | 5,441,868 | 8/15/95 | Lin | | | |
| | A20 | 5,457,038 | 10/10/95 | Trinchieri et al. | | | |
| | A21 | 5,514,582 | 5/7/96 | Capon et al. | | | |
| | A22 | 5,538,866 | 7/23/96 | Israeli et al. | | | |
| | A23 | 5,541,087 | 7/30/96 | Lo et al. | | | |
| | A24 | 5,543,297 | 8/6/96 | Cromlish, et al. | | | |
| | A25 | 5,547,933 | 8/20/96 | Lin | | | |
| | A26 | 5,552,524 | 09/03/96 | Basinski et al. | | | |
| | A27 | 5,585,089 | 12/17/96 | Queen et al. | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO. LEX-023 | | | |
|---|-----|----------------------------|-------------|--|--------------|-----------------------|---------------------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies <i>et al.</i> | | | |
| | | | | SERIAL NO. 10/737,208 | | CONF. NO. 6855 | |
| | | | | FILING DATE: December 16, 2003 | | GROUP: 1653 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| | A28 | 5,601,819 | 2/11/97 | Wong et al. | | | |
| | A29 | 5,609,846 | 3/11/97 | Goldenberg | | | |
| | A30 | 5,618,698 | 4/8/97 | Lin | | | |
| | A31 | 5,624,821 | 4/29/97 | Winter et al. | | | |
| | A32 | 5,639,725 | 6/17/97 | O'Reilly et al. | | | |
| | A33 | 5,645,835 | 7/8/97 | Fell, Jr. et al. | | | |
| | A34 | 5,650,150 | 7/22/97 | Gillies | | | |
| | A35 | 5,650,492 | 7/22/97 | Gately et al. | | | |
| | A36 | 5,667,776 | 9/16/97 | Zimmerman et al. | | | |
| | A37 | 5,679,543 | 10/21/97 | Lawlis | | | |
| | A38 | 5,688,679 | 11/18/97 | Powell | | | |
| | A39 | 5,691,309 | 11/25/97 | Basinski et al. | | | |
| | A40 | 5,709,859 | 1/20/98 | Aruffo et al. | | | |
| | A41 | 5,719,266 | 02/17/98 | DiMarchi et al. | | | |
| | A42 | 5,723,125 | 3/3/98 | Chang et al. | | | |
| | A43 | 5,726,044 | 3/10/98 | Lo et al. | | | |
| | A44 | 5,728,552 | 3/17/98 | Fujisawa et al. | | | |
| | A45 | 5,733,876 | 3/31/98 | O'Reilly et al. | | | |
| | A46 | 5,756,349 | 5/26/98 | Lin | | | |
| | A47 | 5,756,461 | 05/26/98 | Stephens | | | |
| | A48 | 5,759,551 | 6/2/98 | Ladd et al. | | | |
| | A49 | 5,770,195 | 6/23/98 | Hudziak et al. | | | |
| | A50 | 5,800,810 | 9/1/98 | Doyle et al. | | | |
| | A51 | 5,807,715 | 9/15/98 | Morrison et al. | | | |
| | A52 | 5,827,516 | 10/27/98 | Urban et al. | | | |
| | A53 | 5,837,682 | 11/17/98 | Folkman et al. | | | |
| | A54 | 5,843,423 | 12/1/98 | Lyman et al. | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO. LEX-023 | | | |
|---|-----|----------------------------|-------------|--|--------------|-----------------------|---------------------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies <i>et al.</i> | | | |
| | | | | SERIAL NO. 10/737,208 | | CONF. NO. 6855 | |
| | | | | FILING DATE: December 16, 2003 | | GROUP: 1653 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| | A55 | 5,854,205 | 12/29/98 | O'Reilly et al. | | | |
| | A56 | 5,856,298 | 1/5/99 | Strickland | | | |
| | A57 | 5,858,347 | 1/12/99 | Bauer et al. | | | |
| | A58 | 5,885,795 | 3/23/99 | O'Reilly et al. | | | |
| | A59 | 5,886,178 | 3/23/99 | Allen et al. | | | |
| | A60 | 5,888,772 | 3/30/99 | Okasinski et al. | | | |
| | A61 | 5,891,680 | 4/6/99 | Lieschke et al. | | | |
| | A62 | 5,908,626 | 6/1/99 | Chang et al. | | | |
| | A63 | 5,922,685 | 7/13/99 | Rakhmievich et al. | | | |
| | A64 | 5,955,422 | 9/21/99 | Lin | | | |
| | A65 | 5,994,104 | 11/30/99 | Anderson et al. | | | |
| | A66 | 5,994,126 | 11/30/99 | Steinman et al. | | | |
| | A67 | 6,080,409 | 6/27/00 | Laus et al. | | | |
| | A68 | 6,086,875 | 7/11/00 | Blumberg et al. | | | |
| | A69 | 6,100,387 | 8/8/00 | Herrmann et al. | | | |
| | A70 | 6,169,070 | 1/2/01 | Chen et al. | | | |
| | A71 | 6,171,588 | 1/9/01 | Carron et al. | | | |
| | A72 | 6,231,536 | 5/15/01 | Lentz | | | |
| | A73 | 6,277,375 | 8/21/01 | Ward | | | |
| | A74 | 6,284,536 | 9/4/01 | Morrison et al. | | | |
| | A75 | 6,335,176 | 1/1/02 | Inglese et al. | | | |
| | A76 | 6,340,742 | 1/22/02 | Burg et al. | | | |
| | A77 | 6,348,192 | 2/19/02 | Chan et al. | | | |
| | A78 | 6,406,689 | 6/18/02 | Falkenberg et al. | | | |
| | A79 | 6,429,199 | 8/6/02 | Krieg et al. | | | |
| | A80 | 6,444,792 | 9/3/02 | Gray et al. | | | |
| | A81 | 6,475,717 | 11/5/02 | Enssle et al. | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO. LEX-023

APPLICANT(S): Gillies *et al.*

SERIAL NO. 10/737,208

CONF. NO. 6855

FILING DATE: December 16, 2003 GROUP: 1653

U.S. PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|------|--------------------|----------|------------------|-------|--------------|-------------------------------|
| | A82 | 6,485,726 | 11/26/02 | Blumberg et al. | | | |
| | A83 | 6,500,641 | 12/31/02 | Chen et al. | | | |
| | A84 | 6,506,405 | 1/14/03 | Desai et al. | | | |
| | A85 | 6,551,592 | 4/22/03 | Lindhofer et al. | | | |
| | A86 | 6,583,272 | 6/24/03 | Bailon | | | |
| | A87 | 6,586,398 | 7/1/03 | Kinstler et al. | | | |
| | A88 | 6,617,135 | 9/9/03 | Gillies et al. | | | |
| | A89 | 6,646,113 | 11/11/03 | Dreyfuss et al. | | | |
| | A90 | 2001/0053539 | 12/20/01 | Lauffer et al. | | | |
| | A91 | 2002/0037558 | 3/28/02 | Lo et al. | | | |
| | A92 | 2002/0081664 | 6/27/02 | Lo et al. | | | |
| | A93 | 2002/0142374 | 10/3/02 | Gallo et al. | | | |
| | A94 | 2002/0146388 | 10/10/02 | Gillies | | | |
| | A95 | 2002/0147311 | 10/10/02 | Gillies et al. | | | |
| | A96 | 2002/0192222 | 12/19/02 | Blumberg et al. | | | |
| | A97 | 2002/0193570 | 12/19/02 | Gillies et al. | | | |
| | A98 | 2003/0003529 | 1/2/03 | Bayer | | | |
| | A99 | 2003/0044423 | 3/6/03 | Gillies et al. | | | |
| | A100 | 2003/0049227 | 3/13/03 | Gillies et al. | | | |
| | A101 | 2003/0105294 | 6/5/03 | Gillies et al. | | | |
| | A102 | 2003/0012789 | 1/6/03 | Blumberg et al. | | | |
| | A103 | 2003/0139365 | 7/24/03 | Lo et al. | | | |
| | A104 | 2003/0139575 | 7/24/03 | Gillies | | | |
| | A105 | 2003/0157054 | 8/21/03 | Gillies et al. | | | |
| | A106 | 2003/0166163 | 9/4/03 | Gillies | | | |
| | A107 | 2003/0166877 | 9/4/03 | Gillies et al. | | | |
| | A108 | 2004/0013640 | 1/22/04 | Zardi et al. | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

| | | | | | | | |
|---|------|----------------------------|-------------|--|--------------|-----------------------|---------------------------------------|
| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO. LEX-023 | | | |
| INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies <i>et al.</i> | | | |
| | | | | SERIAL NO. 10/737,208 | | CONF. NO. 6855 | |
| | | | | FILING DATE: December 16, 2003 GROUP: 1653 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| | A109 | 2004/0033210 | 2/19/04 | Gillies | | | |
| | A110 | 2004/0043457 | 3/4/04 | Schumacher et al. | | | |
| | A111 | 2004/0053366 | 3/18/04 | Lo et al. | | | |
| | A112 | 2004/0072299 | 4/15/04 | Gillies et al. | | | |
| | A113 | 2004/0082039 | 4/29/04 | Gillies et al. | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

| FORM PTO – 1449 | | | | ATTORNEY DOCKET NO. LEX-023 | | | | | |
|---|-----|--------------------|----------|--|------------------------|----------------|----------------|------------------|--------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies <i>et al.</i> | | | | | |
| | | | | SERIAL NO. 10/737,208 | | CONF. NO. 6855 | | | |
| | | | | FILING DATE: December 16, 2003 GROUP: 1653 | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| | B1 | 0 158 198 A1 | 10/16/85 | EP | | | | | Y |
| | B2 | 0 211 769 A2 | 2/25/87 | EP | | | | | Y |
| | B3 | 0 256 714 A2 | 2/24/88 | EP | | | | | Y |
| | B4 | 0 294 703 A2 | 12/14/88 | EP | | | | | Y |
| | B5 | 0 308 936 B1 | 3/29/89 | EP | | | | | Y |
| | B6 | 0 314 317 B1 | 5/3/89 | EP | | | | | Y |
| | B7 | 0 318 554 B1 | 6/7/89 | EP | | | | | Y |
| | B8 | 0 319 012 A2 | 6/7/89 | EP | | | | | Y |
| | B9 | 0 326 120 B1 | 8/2/89 | EP | | | | | Y |
| | B10 | 0 350 230 A2 | 1/10/90 | EP | | | | | Y |
| | B11 | 0 375 562 B1 | 6/27/90 | EP | | | | | Y |
| | B12 | 0 396 387 A2 | 11/7/90 | EP | | | | | Y |
| | B13 | 0 439 095 A2 | 7/31/91 | EP | | | | | Y |
| | B14 | 0 511 747 A1 | 11/4/92 | EP | | | | | Y |
| | B15 | 0 601 043 B1 | 6/15/94 | EP | | | | | Y |
| | B16 | 0 640 619 A1 | 3/1/95 | EP | | | | | Y |
| | B17 | 0 668 353 A1 | 8/23/95 | EP | | | | | Y |
| | B18 | 0 706 799 A2 | 4/17/96 | EP | | | | | Y |
| | B19 | 0 790 309 A1 | 8/20/97 | EP | | | | | Y |
| | B20 | 1 088 888 A1 | 4/4/01 | EP | | | | | Y |
| | B21 | 21725/88 | 3/23/89 | AU | | | | | Y |
| | B22 | 93100115.3 | 7/14/93 | CN | | | | | N |
| | B23 | 93100115.3 | 7/14/93 | CN | | | | Y | Y |
| | B24 | 37 12985 A1 | 11/2/88 | DE | | | | | N |
| | B25 | 37 12985 | 11/2/88 | DE | | | | Y | Y |
| EXAMINER | | | | | DATE CONSIDERED | | | | |

| FORM PTO – 1449 | | | | | ATTORNEY DOCKET NO. LEX-023 | | | | |
|---|-----|----------------------------|-------------|-------------------------|--|----------------------|------------------------|---|-----------------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | | APPLICANT(S): Gillies <i>et al.</i> | | | | |
| | | | | | SERIAL NO. 10/737,208 CONF. NO. 6855 | | | | |
| | | | | | FILING DATE: December 16, 2003 GROUP: 1653 | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| | B26 | 2 292 382 A | 2/21/96 | GB | | | | | Y |
| | B27 | 63-267278 | 11/4/88 | JP | | | | | N |
| | B28 | 63-267278 | 11/4/88 | JP | | | | Y | Y |
| | B29 | 63-267296 | 11/4/88 | JP | | | | | N |
| | B30 | 63-267296 | 11/4/88 | JP | | | | Y | Y |
| | B31 | 0 237 019 A2 | 9/16/87 | EP | | | | English counterpart of JP 63- 267296 | Y |
| | B32 | WO 86/01533 | 3/13/86 | PCT | | | | | Y |
| | B33 | WO 88/00052 | 1/14/88 | PCT | | | | | Y |
| | B34 | WO 88/09344 | 12/1/88 | PCT | | | | | Y |
| | B35 | WO 89/02922 | 4/6/89 | PCT | | | | | Y |
| | B36 | WO 89/09620 | 10/19/89 | PCT | | | | Abstract in English | N |
| | B37 | WO 90/03801 | 4/19/90 | PCT | | | | | Y |
| | B38 | WO 91/00360 | 1/10/91 | PCT | | | | | Y |
| | B39 | WO 91/04329 | 04/04/91 | PCT | | | | | Y |
| | B40 | WO 91/08298 | 6/13/91 | PCT | | | | | Y |
| | B41 | WO 91/13166 | 9/5/91 | PCT | | | | | Y |
| | B42 | WO 91/14438 | 10/3/91 | PCT | | | | | Y |
| | B43 | WO 92/02240 | 2/20/92 | PCT | | | | | Y |
| | B44 | WO 92/08495 | 5/29/92 | PCT | | | | | Y |
| | B45 | WO 92/08801 | 5/29/92 | PCT | | | | | Y |
| | B46 | WO 92/16562 | 10/1/92 | PCT | | | | | Y |
| | B47 | WO 93/03157 | 2/18/93 | PCT | | | | | Y |
| | B48 | WO 93/10229 | 5/27/93 | PCT | | | | | Y |
| | B49 | WO 93/20185 | 10/14/93 | PCT | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | | | |

| FORM PTO – 1449 | | | | | ATTORNEY DOCKET NO. LEX-023 | | | | |
|---|-----|----------------------------|-------------|-------------------------|--|----------------------|------------------------|--------------------------|-----------------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | | APPLICANT(S): Gillies <i>et al.</i> | | | | |
| | | | | | SERIAL NO. 10/737,208 CONF. NO. 6855 | | | | |
| | | | | | FILING DATE: December 16, 2003 GROUP: 1653 | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| | B50 | WO 94/24160 | 10/27/94 | PCT | | | | | Y |
| | B51 | WO 94/25055 | 11/10/94 | PCT | | | | | Y |
| | B52 | WO 95/05468 | 2/23/95 | PCT | | | | | Y |
| | B53 | WO 95/21258 | 8/10/95 | PCT | | | | | Y |
| | B54 | WO 95/28427 | 10/26/95 | PCT | | | | | Y |
| | B55 | WO 95/31483 | 11/23/95 | PCT | | | | | Y |
| | B56 | WO 96/04388 | 02/15/96 | PCT | | | | | Y |
| | B57 | WO 96/05309 | 2/22/96 | PCT | | | | | Y |
| | B58 | WO 96/08570 | 3/21/96 | PCT | | | | | Y |
| | B59 | WO 96/18412 | 6/20/96 | PCT | | | | | Y |
| | B60 | WO 96/31526 | 10/10/96 | PCT | | | | | Y |
| | B61 | WO 97/00317 | 1/3/97 | PCT | | | | | Y |
| | B62 | WO 97/00319 | 1/3/97 | PCT | | | | | Y |
| | B63 | WO 97/15666 | 5/1/97 | PCT | | | | | Y |
| | B64 | WO 97/20062 | 6/5/97 | PCT | | | | | Y |
| | B65 | WO 97/24137 | 7/10/97 | PCT | | | | | Y |
| | B66 | WO 97/24440 | 7/10/97 | PCT | | | | | Y |
| | B67 | WO 97/26335 | 7/24/97 | PCT | | | | | Y |
| | B68 | WO 97/30089 | 8/21/97 | PCT | | | | | Y |
| | B69 | WO 97/33617 | 9/18/97 | PCT | | | | | Y |
| | B70 | WO 97/33619 | 9/18/97 | PCT | | | | | Y |
| | B71 | WO 97/34631 | 9/25/97 | PCT | | | | | Y |
| | B72 | WO 97/43316 | 11/20/97 | PCT | | | | | Y |
| | B73 | WO 98/00127 | 1/8/98 | PCT | | | | | Y |
| | B74 | WO 98/06752 | 2/19/98 | PCT | | | | | Y |
| | B75 | WO 98/28427 | 7/2/98 | PCT | | | | | Y |
| EXAMINER | | | | | DATE CONSIDERED | | | | |

| FORM PTO – 1449 | | | | | ATTORNEY DOCKET NO. LEX-023 | | | | |
|---|------|----------------------------|-------------|-------------------------|--|----------------------|------------------------|--------------------------|-----------------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | | APPLICANT(S): Gillies <i>et al.</i> | | | | |
| | | | | | SERIAL NO. 10/737,208 CONF. NO. 6855 | | | | |
| | | | | | FILING DATE: December 16, 2003 GROUP: 1653 | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| | B76 | WO 98/30706 | 7/16/98 | PCT | | | | | Y |
| | B77 | WO 98/46257 | 10/22/98 | PCT | | | | | Y |
| | B78 | WO 98/59244 | 12/30/98 | PCT | | | | | Y |
| | B79 | WO 99/02709 | 01/21/99 | PCT | | | | | Y |
| | B80 | WO 99/03887 | 01/28/99 | PCT | | | | | Y |
| | B81 | WO 99/29732 | 6/17/99 | PCT | | | | | Y |
| | B82 | WO 99/43713 | 9/2/99 | PCT | | | | | Y |
| | B83 | WO 99/52562 | 10/21/99 | PCT | | | | | Y |
| | B84 | WO 99/53958 | 10/28/99 | PCT | | | | | Y |
| | B85 | WO 99/60128 | 11/25/99 | PCT | | | | | Y |
| | B86 | WO 99/62944 | 12/09/99 | PCT | | | | | Y |
| | B87 | WO 99/66054 | 12/23/99 | PCT | | | | | Y |
| | B88 | WO 00/11033 | 3/2/00 | PCT | | | | | Y |
| | B89 | WO 00/24893 | 5/4/00 | PCT | | | | | |
| | B90 | WO 00/34317 | 06/15/00 | PCT | | | | | Y |
| | B91 | WO 00/40615 | 7/13/00 | PCT | | | | | Y |
| | B92 | WO 00/68376 | 11/16/00 | PCT | | | | | Y |
| | B93 | WO 00/69913 | 11/23/00 | PCT | | | | | Y |
| | B94 | WO 00/78334 | 12/28/00 | PCT | | | | | Y |
| | B95 | WO 01/07081 | 2/1/01 | PCT | | | | | Y |
| | B96 | WO 01/10912 | 2/15/01 | PCT | | | | | Y |
| | B97 | WO 01/36489 | 5/25/01 | PCT | | | | | Y |
| | B98 | WO 01/58957 | 8/16/01 | PCT | | | | | |
| | B99 | WO 02/02143 | 1/10/02 | PCT | | | | | |
| | B100 | WO 02/066514 | 8/29/02 | PCT | | | | | Y |
| | B101 | WO 02/072605 | 9/19/02 | PCT | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | | | |

| | | | | | | | | | |
|---|------|----------------------------|-------------|-------------------------|--|----------------------|------------------------|--------------------------|-----------------------------------|
| FORM PTO – 1449 | | | | | ATTORNEY DOCKET NO. LEX-023 | | | | |
| INFORMATION DISCLOSURE STATEMENT | | | | | APPLICANT(S): Gillies <i>et al.</i> | | | | |
| | | | | | SERIAL NO. 10/737,208 CONF. NO. 6855 | | | | |
| | | | | | FILING DATE: December 16, 2003 GROUP: 1653 | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| | B102 | WO 02/079232 | 10/10/02 | PCT | | | | | |
| | B103 | WO 02/079415 | 10/10/02 | PCT | | | | | |
| | B104 | WO 02/090566 | 11/14/02 | PCT | | | | | |
| | B105 | WO 03/015697 | 2/27/03 | PCT | | | | | Y |
| | B106 | WO 03/048334 | 6/12/03 | PCT | | | | | |
| | B107 | WO 03/077834 | 9/25/03 | PCT | | | | | Y |
| EXAMINER | | | | | DATE CONSIDERED | | | | |

| | | | |
|---|---|---|--|
| FORM PTO – 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO. LEX-023 APPLICANT(S): Gillies <i>et al.</i> SERIAL NO. 10/737,208 CONF. NO. 6855 FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C1 | Abaza et al., (1992), "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin," <u>Journal of Protein Chemistry</u> , 11(5):433-444. | |
| | C2 | Abstract XP-002116766, Lupulescu, (1996), "Prostaglandins, Their Inhibitors and Cancer," <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , 54(2):83-94. | |
| | C3 | Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237. | |
| | C4 | Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30(1):105-108. | |
| | C5 | Arenberg et al., (1996), "Interferon- γ -inducible Protein 10 (IP-10) is an Angiostatic Factor that Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , 184:981-992. | |
| | C6 | Bacha et al., (1988), "Interleukin 2 Receptor-Targeted Cytotoxicity: Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein," <u>J. Exp. Med.</u> , 167:612-622. | |
| | C7 | Bachelot et al., (1998), "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion Protein with Enhanced Anti-Tumor Properties In Vivo," <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , 39:271, Abstract #1856 (XP-002089298). | |
| | C8 | Barnett et al., (1994), "Purification, Characterization and Selective Inhibition of Human Prostaglandin G/H Synthase 1 and 2 Expressed in the Baculovirus System," <u>Biochimica et Biophysica Acta</u> , 1209:130-139. | |
| | C9 | Baselga et al., (1998), "Recombinant Humanized Anti-HER2 Antibody (Herceptin TM) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER3/ <i>neu</i> Overexpressing Human Breast Cancer Xenografts," <u>Cancer Research</u> , 58:2825-2831. | |
| | C10 | Batova et al., (1999), "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , 5:4259-4263. | |
| | C11 | Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Molecular Immunology</u> , 30(4):379-386. | |
| | C12 | Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci. USA</u> , 93:7826-7831. | |
| | C13 | Becker et al., (1996), "Eradication of Human Hepatic and Pulmonary Melanoma Metastases in SCID Mice by Antibody-interleukin 2 Fusion Proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 93:2702-2707. | |
| | C14 | Becker et al., (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <u>J. Clin. Invest.</u> , 98(12):2801-2804. | |
| | C15 | Becker et al., (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <u>J. Exp. Med.</u> , 183(50):2361-2366. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|--|--|
| FORM PTO – 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO. LEX-023 APPLICANT(S): Gillies <i>et al.</i> SERIAL NO. 10/737,208 CONF. NO. 6855 FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C16 | Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <u>Annual Rev. Biochem.</u> , 57:505-518. | |
| | C17 | Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher (ed.), pp. 175-193. | |
| | C18 | Bitonti et al., (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312. | |
| | C19 | Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," <u>Cancer Research</u> , 45:1214-1221. | |
| | C20 | Boehm et al., (1997), "Antiangiogenic Therapy of Experimental Cancer Does Not Induce Acquired Drug Resistance," <u>Nature</u> , 390:404-407. | |
| | C21 | Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , 252:190-194. | |
| | C22 | Boissel et al., (1993), "Erythropoietin Structure-Function Relationships: Mutant Proteins that Test a Model of Tertiary Structure," <u>The Journal of Biological Chemistry</u> , 268(21):15983-15993. | |
| | C23 | Briggs et al., (1974), "Hepatic Clearance of Intact and Desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227(6):1385-1388. | |
| | C24 | Brooks et al., (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , 79:1157-1164. | |
| | C25 | Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307(2):411-415. | |
| | C26 | Burgess et al., (1990), "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , 111:2129-2138. | |
| | C27 | Canfield et al., (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>J. Exp. Med.</u> , 173(6):1483-1491. | |
| | C28 | Cao et al., (1996), "Kringle Domains of Human Angiostatin: Characterization of the Anti-Proliferative Activity of Endothelial Cells," <u>The Journal of Biological Chemistry</u> , 271(46):29461-29467. | |
| | C29 | Cao et al., (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , 272(36):22924-22928. | |
| | C30 | Capon et al., (1989), "Designing CD4 Immunoadhesins for AIDS Therapy," <u>Nature</u> , 337:525-531. | |
| | C31 | Caton et al., (1986), "Structural and Functional Implications of a Restricted Antibody Response to a Defined Antigenic Region on the Influenza Virus Hemagglutinin," <u>The EMBO Journal</u> , 5(7):1577-1587. | |
| | C32 | Chan et al., (1991), "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , 173: 869-879. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|--|-----------------------|
| FORM PTO – 1449 | | ATTORNEY DOCKET NO. LEX-023 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | |
| | | SERIAL NO. 10/737,208 | CONF. NO. 6855 |
| | | FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C33 | Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , 5:385-390. | |
| | C34 | Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271(23):13349-13355. | |
| | C35 | Chapman et al., (1994), "Mapping Effector Functions of a Monoclonal Antibody to GD3 by Characterization of a Mouse-Human Chimeric Antibody," <u>Cancer Immuno. Immunother.</u> , 39:198-204. | |
| | C36 | Chaudhary et al., (1988), "Selective Killing of HIV-infected Cells by Recombinant Human CD4- <i>Pseudomonas</i> Exotoxin Hybrid Protein," <u>Nature</u> , 335:370-372. | |
| | C37 | Chaudhary et al., (1989), "A Recombinant Immunotoxin Consisting of Two Antibody Variable Domains Fused to <i>Pseudomonas</i> Exotoxin," <u>Nature</u> , 339:394-397. | |
| | C38 | Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , 159(1):351-358. | |
| | C39 | Cheon et al., (1994), "High-affinity Binding Sites for Related Fibroblast Growth Factor Ligands Reside Within Different Receptor Immunoglobulin-like Domains," <u>Proc. Natl. Acad. Sci. USA</u> , 91: 989-993. | |
| | C40 | Chuang et al., (1993), "Effect of New Investigational Drug Taxol on Oncolytic Activity and Stimulation of Human Lymphocytes," <u>Gynecologic Oncology</u> , 49:291-298. | |
| | C41 | Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291. | |
| | C42 | Cohen et al., (1996), "Human Leptin Characterization," <u>Nature</u> , 382:589. | |
| | C43 | Cole et al., (1997), "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , 159:3613-3621. | |
| | C44 | Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 That Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 85:7709-7713. | |
| | C45 | Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , 56:2531-2534. | |
| | C46 | Conner et al., (2004), "Ex vivo Evaluation of Anti-EpCAM Immunocytokine huKS-IL2 in Ovarian Cancer," <u>J. Immunotherapy</u> , 27:211-219. | |
| | C47 | Cruse et al., (eds.), (1995), <u>Illustrated Dictionary of Immunology</u> , pp.156-158, CRC Press, NY. | |
| | C48 | D'Amato et al., (1994), "Thalidomide is an Inhibitor of Angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , 91:4082-4085. | |
| | C49 | D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , 176:1387-1398. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|---|-----------------------|
| FORM PTO – 1449 | | ATTORNEY DOCKET NO. LEX-023 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | |
| | | SERIAL NO. 10/737,208 | CONF. NO. 6855 |
| | | FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C50 | Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531. | |
| | C51 | Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308. | |
| | C52 | de la Salle et al., (1996), "FcγR on Human Dendritic Cells," in <u>Human IgG Receptors</u> , pp. 39-55, van de Winkel et al. (eds.), R.G. Landes Co. | |
| | C53 | Ding et al., (1988), "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin," <u>Proc. Natl. Acad. Sci. USA</u> , 95:10443-10448. | |
| | C54 | Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin. Cancer Research</u> , 4(10):2551-2557. | |
| | C55 | Dorai et al., (1991), "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function," <u>Hybridoma</u> , 10(2):211-217. | |
| | C56 | Dorai et al., (1992), "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human IgG1," <u>Molecular Immunology</u> , 29(12):1487-1491. | |
| | C57 | Duncan et al., (1988), "The Binding Site for C1q on IgG," <u>Nature</u> , 332:738-740. | |
| | C58 | Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem., Supp.</u> , 161:156-166. | |
| | C59 | Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16(Suppl 3):3-13. | |
| | C60 | Eisenthal, (1990), "Indomethacin Up-regulates the Generation of Lymphokine-Activated Killer-cell Activity and Antibody-dependent Cellular Cytotoxicity Mediated by Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 31:342-348. | |
| | C61 | Elliott et al., (1996), "Fine-Structure Epitope Mapping of Antierythropoietin Monoclonal Antibodies Reveals a Model of Recombinant Human Erythropoietin Structure," <u>Blood</u> , 87(7):2702-2713. | |
| | C62 | Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502. | |
| | C63 | Fell et al., (1991), "Genetic Construction and Characterization of A Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>J. Immunology</u> , 146(7):2446-2452. | |
| | C64 | Fell et al., (1992), "Chimeric L6 Anti-tumor Antibody: Genomic Construction, Expression, and Characterization of the Antigen Binding Site," <u>J. Biological Chemistry</u> , 267:15552-15558. | |
| | C65 | Fibi et al., (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85(5):1229-1236. | |
| | C66 | Friedman et al., (1998), "Leptin and the Regulation of Body Weight in Mammals," <u>Nature</u> , 395:763-770. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|--|-----------------------|
| FORM PTO – 1449 | | ATTORNEY DOCKET NO. LEX-023 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | |
| | | SERIAL NO. 10/737,208 | CONF. NO. 6855 |
| | | FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C67 | Frost et al., (1997), "A Phase I/IB Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80(2):317-333. | |
| | C68 | Gan et al., (1999), "Specific Enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clinical and Diagnostic Laboratory Immunology</u> , 6(2):236-42. | |
| | C69 | Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," <u>Science</u> , 226:1339-1342. | |
| | C70 | Gately et al., (1998), "The Interleukin-12/Interleukin-12-Receptor System: Role in Normal and Pathologic Immune Responses," <u>Annu. Rev. Immunol.</u> , 16:495-521. | |
| | C71 | Gillesen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist," <u>Eur. J. Immunol.</u> , 25:200-206. | |
| | C72 | Gillies et al., (1989), "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , 7:799-804. | |
| | C73 | Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , 125:191-202. | |
| | C74 | Gillies et al., (1990), "Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities," <u>Hum. Antibod. Hybridomas</u> , 1(1):47-54. | |
| | C75 | Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56. | |
| | C76 | Gillies et al., (1991), "Targeting Human Cytotoxic T Lymphocytes to Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells: Tumor-Infiltrating Lymphocyte/Hormone Receptor/Recombinant Antibody," <u>J. Immunology</u> , 146(3):1067-1071. | |
| | C77 | Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 89:1428-1432. | |
| | C78 | Gillies et al., (1993), "Biological Activity and <i>In Vivo</i> Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4(3):230-235. | |
| | C79 | Gillies et al., (1998), "Antibody-IL-12 Fusion Proteins are Effective in SCID Mouse Models of Prostate and Colon Carcinoma Metastases," <u>J. Immunology</u> , 160:6195-6203. | |
| | C80 | Gillies et al., (1999), "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," <u>Cancer Research</u> , 59:2159-2166. | |
| | C81 | Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60. | |
| | C82 | Gillies et al., (2002), "Improved Circulating Half-life and Efficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Research</u> , 8(1):210-216. | |
| | C83 | Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>J. Immunology</u> , 120(6):2027-2032. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|---|-----------------------|
| FORM PTO – 1449 | | ATTORNEY DOCKET NO. LEX-023 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | |
| | | SERIAL NO. 10/737,208 | CONF. NO. 6855 |
| | | FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C84 | Goeddel et al., (1986), "Tumor Necrosis Factors: Gene Structure and Biological Activities," <u>Cold Spring Harb. Symp. Quant. Biol.</u> , 51:597-609. | |
| | C85 | Greene et al., (1975), "Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927. | |
| | C86 | Gren et al., (1983), "A New Type of Leukocytic Interferon," English Translation of <u>Dokl. Akad. Nauk. SSSR.</u> , 269(4):986-990. | |
| | C87 | Griffon-Etienne et al., (1999), "Taxane-induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: Clinical Implications," <u>Cancer Research</u> , 59:3776-3782. | |
| | C88 | Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , 73(8):2081-2085. | |
| | C89 | Guyre et al., (1997), "Increased Potency of Fc-receptor-targeted Antigens," <u>Cancer Immunol. Immunother.</u> , 45:146-148. | |
| | C90 | Hammerling et al., (1996), "In Vitro Bioassay for Human Erythropoietin Based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Carbohydrate-dependent Microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469. | |
| | C91 | Handgretinger et al., (1995), "A Phase I Study of Human/Mouse Chimeric Anti-ganglioside GD2 Antibody ch14.18 in Patients with Neuroblastoma," <u>European J. Cancer</u> , 31A(2):261-267. | |
| | C92 | Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Research</u> , 2(12):1951-1959. | |
| | C93 | Hank et al., (2003), "Determination of Peak Serum Levels and Immune Response to the Humanized Anti-ganglioside Antibody-interleukin-2 Immunocytokine," in <u>Methods in Molecular Medicine</u> , Vol. 85: <u>Novel Anticancer Drug Protocols</u> , Buolamwini et al., (eds.), pp. 123-131, Humana Press Inc., Totowana, NJ. | |
| | C94 | Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 α -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-10459. | |
| | C95 | Harris et al., (1993), "Therapeutic Antibodies - the Coming of Age," <u>Trends in Biotechnology</u> , 11:42-44. | |
| | C96 | Harris, (1995), "Processing of C-terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture," <u>J. Chromatography A</u> , 705:129-134. | |
| | C97 | Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds Fc γ RI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotechnology</u> , 1:95-105. | |
| | C98 | Harvill et al., (1996), "In Vivo Properties of an IgG3-IL-2 Fusion Protein: A General Strategy for Immune Potentiation," <u>J. Immunology</u> , 157(7):3165-3170. | |
| | C99 | Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , 11(6):629-636. | |
| | C100 | He et al., (1998), "Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-Selectin," <u>J. Immunology</u> , 160:1029-1035. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|---|-----------------------|
| FORM PTO – 1449 | | ATTORNEY DOCKET NO. LEX-023 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | |
| | | SERIAL NO. 10/737,208 | CONF. NO. 6855 |
| | | FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C101 | Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human FcγRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , 97(2):331-338. | |
| | C102 | Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers," <u>J. Immunology</u> , 158:4381-4388. | |
| | C103 | Hellstrom et al., (1986), "Antitumor Effects of L6, an IgG2a Antibody that Reacts with Most Human Carcinomas," <u>Proc. Natl. Acad. Sci. USA</u> , 83: 7059-7063. | |
| | C104 | Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , 3:31-58. | |
| | C105 | Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , 7(2):159-167. | |
| | C106 | Hezareh et al., (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virology</u> , 75(24):12161-12168. | |
| | C107 | Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution," <u>EMBO Journal</u> , 17(6):1656-1664. | |
| | C108 | Holden et al., (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," <u>Proceedings of the American Association for Cancer Research</u> , 42:683, Abstract No. 3675 (XP-002195344). | |
| | C109 | Holden et al., (2001), "Augmentation of Antitumor Activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents," <u>Clinical Cancer Research</u> , 7:2862-2869. | |
| | C110 | Hoogenboom et al., (1991), "Construction and Expression of Antibody-tumor Necrosis Factor Fusion Proteins," <u>Molecular Immunology</u> , 28(9):1027-1037. | |
| | C111 | Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , 1096(4):345-354 (Abstract). | |
| | C112 | Hornick et al., (1999), "Pretreatment with a Monoclonal Antibody/Interleukin-2 Fusion Protein Directed Against DNA Enhances the Delivery of Therapeutic Molecules to Solid Tumors," <u>Clin. Cancer Research</u> , 5:51-60. | |
| | C113 | Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004. | |
| | C114 | Huck et al., (1986), "Sequence of a Human Immunoglobulin Gamma 3 Heavy Chain Constant Region Gene: Comparison With the Other Human Cγ genes," <u>Nucleic Acids Research</u> , 14(4):1779-1789. | |
| | C115 | Hurn et al., (1980), "Production of Reagent Antibodies," <u>Methods in Enzymology</u> , 70: 104-142. | |
| | C116 | Huse et al., (1989), "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246:1275-1281. | |
| | C117 | Idusogie et al., (2000), "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunology</u> , 164(8):4178-4184. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|--|-----------------------|
| FORM PTO – 1449 | | ATTORNEY DOCKET NO. LEX-023 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | |
| | | SERIAL NO. 10/737,208 | CONF. NO. 6855 |
| | | FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C118 | Imboden et al., (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <u>Cancer Research</u> , 61(4):1500-7. | |
| | C119 | Ingber et al., (1990), "Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumour Growth," <u>Nature</u> , 348:555-557. | |
| | C120 | Isenman et al., (1975), "The Structure and Function of Immunoglobulin Domains: II. The Importance of Interchain Disulfide Bonds and the Possible Role of Molecular Flexibility in the Interaction between Immunoglobulin G and Complement," <u>J. Immunology</u> , 114(6):1726-1729. | |
| | C121 | Jones et al., (1986), "Replacing the Complementarity-determining Regions in a Human Antibody with Those from a Mouse," <u>Nature</u> , 321:522-525. | |
| | C122 | Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2: Identification of Amino Acid Residues for Biological Activity," <u>Journal of Biological Chemistry</u> , 262(12):5723-5731. | |
| | C123 | Jung et al., (1986), "Activation of Human Peripheral Blood Mononuclear Cells by Anti-T3: Killing of Tumor Target Cells Coated with Anti-target-anti-T3 Conjugates," <u>Proc. Natl. Acad. Sci. USA</u> , 83:4479-4483. | |
| | C124 | Junghans et al., (1996), "The Protection Receptor of IgG Catabolism is the B2-microglobulin-containing Neonatal Intestinal Transport Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 93(11):5512-5516. | |
| | C125 | Kang et al., (1991), "Antibody Redesign by Chain Shuffling from Random Combinatorial Immunoglobulin Libraries," <u>Proc. Natl. Acad. Sci. USA</u> , 88:11120-11123. | |
| | C126 | Kappel et al., (1992), "Regulating Gene Expression in Transgenic Animals," <u>Current Opinion in Biotechnology</u> , 3:548-553 | |
| | C127 | Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527. | |
| | C128 | Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26(2):126-131. | |
| | C129 | Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFcγ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , 160(6):1686-1701. | |
| | C130 | Kendra et al., (1999), "Pharmacokinetics and Stability of the ch14.18-Interleukin-2 Fusion Protein in Mice," <u>Cancer Immunol. Immunother.</u> , 48:219-229. | |
| | C131 | Kim et al., (1997), "An Ovalbumin-IL-12 Fusion Protein is More Effective than Ovalbumin Plus Free Recombinant IL-12 in Inducing a T Helper Cell Type 1-dominated Immune Response and Inhibiting Antigen-Specific IgE Production," <u>J. Immunology</u> , 158(9):4137-4144. | |
| | C132 | Kim et al., (1999), "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," <u>Journal of Interferon and Cytokine Research</u> , 19:77-84. | |
| | C133 | Kitamura et al., (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <u>Journal of Cellular Physiology</u> , 140:323-334. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|--|-----------------------|
| FORM PTO – 1449 | | ATTORNEY DOCKET NO. LEX-023 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | |
| | | SERIAL NO. 10/737,208 | CONF. NO. 6855 |
| | | FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C134 | Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocytokine EMD 273066 (huKS-IL2)," <u>J. Immunotherapy</u> , 27:232-239. | |
| | C135 | Kranz et al., (1984), "Attachment of an Anti-receptor Antibody to Non-target Cells Renders Them Susceptible to Lysis by a Clone of Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci. USA</u> , 81:7922-7926. | |
| | C136 | Kuo et al., (2001), "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , 152(6):1233-1246. | |
| | C137 | Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma," <u>J. Clinical Oncology</u> , 19(22):4189-94. | |
| | C138 | LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , 268(31):23311-23317. | |
| | C139 | Lazar et al., (1988), "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> , 8(3):1247-1252. | |
| | C140 | LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , 51:2694-2698. | |
| | C141 | Lieschke, et al., (1997), "Bioactive Murine and Human Interleukin-12 Fusion Proteins which Retain Antitumor Activity In Vivo," <u>Nature Biotechnology</u> , 15(1):35-40. | |
| | C142 | Linsley et al., (1991), "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>J. Exp. Med.</u> , 174(3):561-569. | |
| | C143 | Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci. USA</u> , 82:8648-8652. | |
| | C144 | Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , 239:395-398. | |
| | C145 | Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 92(10):3730-3736. | |
| | C146 | Lo et al., (1992), "Expression and Secretion of an Assembled Tetrameric CH2-deleted Antibody in <i>E. Coli.</i> ," <u>Hum. Antibod. Hybridomas</u> , 3:123-128. | |
| | C147 | Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," <u>Protein Engineering</u> , 11(6):495-500. | |
| | C148 | Locatelli et al., (2001), "Darbepoetin alfa Amgen," <u>Current Opinion in Investigational Drugs</u> , 2:1097-1104. | |
| | C149 | Lode et al., (1997), "Targeted Interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <u>J. Natl. Cancer Inst.</u> , 89(21):1586-94. | |
| | C150 | Lode et al., (1998), "Immunocytokines: A Promising Approach to Cancer Immunotherapy," <u>Pharmacol. Ther.</u> , 80(3):277-292. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|--|--|
| FORM PTO – 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO. LEX-023 APPLICANT(S): Gillies <i>et al.</i> SERIAL NO. 10/737,208 CONF. NO. 6855 FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C151 | Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , 91(5):1706-1715. | |
| | C152 | Lode et al., (1999), "Synergy Between an Antiangiogenic Integrin α_v Antagonist and an Antibody-cytokine Fusion Protein Eradicates Spontaneous Tumor Metastases," <u>Proc. Natl. Acad. Sci. USA</u> , 96:1591-1596. | |
| | C153 | Lode et al., (1999), "Tumor-targeted IL-2 Amplifies T Cell-mediated Immune Response Induced by Gene Therapy with Single-chain IL-12," <u>Proc. Natl. Acad. Sci. USA</u> , 96:8591-8596. | |
| | C154 | Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , 29(2):117-120. | |
| | C155 | Lode et al., (2000), "What To Do With Targeted IL-2," <u>Drugs of Today</u> , 36(5):321-336. | |
| | C156 | Lode et al., (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30. | |
| | C157 | Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17(Suppl 5):66-70. | |
| | C158 | Maecker et al., (1997), "DNA Vaccination with Cytokine Fusion Constructs Biases the Immune Response to Ovalbumin," <u>Vaccine</u> , 15(15):1687-1696. | |
| | C159 | Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , 84(8):2457-2466. | |
| | C160 | Mark et al., (1992), "Expression and Characterization of Hepatocyte Growth Factor Receptor-IgG Fusion Proteins," <u>Journal of Biological Chemistry</u> , 267(36):26166-26171. | |
| | C161 | Martinotti et al., (1995), "CD4 T Cells Inhibit <i>In Vivo</i> the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> 25:137-146. | |
| | C162 | Medesan et al., (1997), "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1," <u>J. Immunology</u> , 158(5):2211-2217. | |
| | C163 | Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on Fc γ RII (CD32) and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <u>Blood</u> , 99(11):4166-73. | |
| | C164 | Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of Cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , 57:2890-2895. | |
| | C165 | Mosmann et al., (1989), "TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> , 7:145-173. | |
| | C166 | Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994. | |
| | C167 | Mueller et al., (1990), "Enhancement of Antibody-Dependent Cytotoxicity With A Chimeric Anti-GD2 Antibody," <u>J. Immunology</u> , 144(4):1382-1386 | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|---|--|
| FORM PTO – 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO. LEX-023 APPLICANT(S): Gillies <i>et al.</i> SERIAL NO. 10/737,208 CONF. NO. 6855 FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C168 | Mueller et al., (1990), "Serum Half-Life and Tumor Localization of a Chimeric Antibody Deleted of the CH2 Domain and Directed Against the Disialoganglioside GD2," <u>Proc. Natl. Acad. Sci. USA</u> , 87:5702-5705. | |
| | C169 | Mueller et al., (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <u>Molecular Immunology</u> , 34(6):441-452. | |
| | C170 | Mullins et al., (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> , 45:20-28. | |
| | C171 | Mullins et al., (1998), "Interleukin-12 Overcomes Paclitaxel-mediated Suppression of T-cell Proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20(4):473-492. | |
| | C172 | Murphy et al., (1986), "Genetic Construction, Expression, and Melanoma-selective Cytotoxicity of a Diphtheria Toxin-related α -melanocyte-stimulating Hormone Fusion Protein," <u>Proc. Natl. Acad. Sci. USA</u> , 83:8258-8262. | |
| | C173 | Murphy, (1988), "Diphtheria-related Peptide Hormone Gene Fusions: A Molecular Gene Approach to Chimeric Toxin Development," in <u>Immunotoxins</u> , pp. 123-140, Frankel (ed.), Kluwer Acad. Pub. | |
| | C174 | Naramura et al., (1993), "Therapeutic Potential of Chimeric and Murine Anti-(Epidermal Growth Factor Receptor) Antibodies in a Metastasis Model for Human Melanoma," <u>Cancer Immuno. Immunother.</u> , 37:343-349. | |
| | C175 | Naramura et al., (1994), "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein Against Human Melanoma Cells," <u>Immunology Letters</u> , 39:91-99. | |
| | C176 | Neal et al., (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol. Immunother.</u> , 53:41-52. | |
| | C177 | Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , 13(17):6361-6373. | |
| | C178 | Netti et al., (1995), "Time-dependent Behavior of Interstitial Fluid Pressure in Solid Tumors: Implications for Drug Delivery," <u>Cancer Research</u> , 55:5451-5458. | |
| | C179 | Netti et al., (1999), "Enhancement of Fluid Filtration Across Tumor Vessels: Implication for Delivery of Macromolecules," <u>Proc. Nat. Acad. Sci. USA</u> , 96:3137-3142. | |
| | C180 | Neuberger et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , 312:604-608. | |
| | C181 | Ngo et al., (1994), "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , Merz et al. (eds.), pp. 433-440 and 492-495, Birkhauser, Boston, MA. | |
| | C182 | Niethammer et al., (2002) "An Oral DNA Vaccine Against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-429. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|---|--|
| FORM PTO – 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO. LEX-023 APPLICANT(S): Gillies <i>et al.</i> SERIAL NO. 10/737,208 CONF. NO. 6855 FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C183 | Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma," <u>Cancer Research</u> , 61(16):6178-84. | |
| | C184 | Nimtz et al., (1993), "Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56. | |
| | C185 | O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , 79:315-328. | |
| | C186 | O'Reilly et al., (1996), "Angiostatin Induces and Sustains Dormancy of Human Primary Tumors in Mice," <u>Nature Medicine</u> , 2(6):689-692. | |
| | C187 | O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , 88:277-285. | |
| | C188 | Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92. | |
| | C189 | Park et al., (2000), "Efficiency of Promoter and Cell Line in High-level Expression of Erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172. | |
| | C190 | Pastan et al., (1989), " <i>Pseudomonas</i> Exotoxin: Chimeric Toxins," <u>Journal of Biological Chemistry</u> , 264(26):15157-15160. | |
| | C191 | Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , 6:407-438. | |
| | C192 | Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target Cell Antibodies," <u>J. Exp. Med.</u> , 163:166-178. | |
| | C193 | Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>J. Immunology</u> , 142(10):3662-3667. | |
| | C194 | Pertl et al., (2003), "Immunotherapy with a Posttranscriptionally Modified DNA Vaccine Induces Complete Protection Against Metastatic Neuroblastoma," <u>Blood</u> , 101(2):649-654. | |
| | C195 | Polizzi et al., (1999), "A Novel Taxane with Improved Tolerability and Therapeutic Activity in a Panel of Human Tumor Xenografts," <u>Cancer Research</u> , 59:1036-1040. | |
| | C196 | Putzer et al., (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Natl. Acad. Sci. USA</u> , 94(20):10889-10894. | |
| | C197 | Reisfeld et al., (1994), "Potential of Genetically Engineered Anti-Ganglioside GD2 Antibodies for Cancer Immunotherapy," <u>Prog. Brain Res.</u> , 101:201-212 | |
| | C198 | Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J. Clin. Lab. Anal.</u> , 10:160-166. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|--|--|
| FORM PTO – 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO. LEX-023 APPLICANT(S): Gillies <i>et al.</i> SERIAL NO. 10/737,208 CONF. NO. 6855 FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C199 | Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic <i>nu/nu</i> Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Research</u> , 56(8):1707-1712. | |
| | C200 | Reisfeld et al., (1996), "Recombinant Antibody Fusion Proteins for Cancer Immunotherapy," <u>Current Topics in Microbiology and Immunology</u> , 213:27-53. | |
| | C201 | Reisfeld et al., (1997), "Immunocytokines: A New Approach to Immunotherapy of Melanoma," <u>Melanoma Research</u> , 7(Supp2):S99-S106. | |
| | C202 | Riethmuller et al., (1994), "Randomised Trial of Monoclonal Antibody for Adjuvant Therapy of Resected Dukes' C Colorectal Carcinoma," <u>The Lancet</u> , 343:1177-1183. | |
| | C203 | Roessler et al., (1994), "Cooperative Interactions Between the Interleukin 2 Receptor α and β Chains Alter the Interleukin 2-binding Affinity of the Receptor Subunits," <u>Proc. Natl. Acad. Sci. USA</u> , 91:3344-3347. | |
| | C204 | Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , 3 rd Ed., pp. 8.3-8.4. | |
| | C205 | Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: Current Status and Future Prospects," <u>Immunology Today</u> , 9(2):58-62. | |
| | C206 | Rozwarski et al., (1994), "Structural Comparisons Among the Short-chain Helical Cytokines," <u>Structure</u> , 2(3):159-173. | |
| | C207 | Ruehlmann et al., (2001), "MIG (CXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Research</u> , 61(23):8498-503. | |
| | C208 | Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30. | |
| | C209 | Saleh et al., (1992), "Phase I Trial of the Chimeric Anti-GD2 Monoclonal Antibody ch14.18 in Patients With Malignant Melanoma," <u>Hum. Antib. Hybridomas</u> , 3:19-24. | |
| | C210 | Sallusto et al., (1994), "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α ," <u>J. Exp. Med.</u> , 179:1109-1118. | |
| | C211 | Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , 46:4701-4705. | |
| | C212 | Sasaki et al., (1998), "Structure, Function and Tissue Forms of the C-terminal Globular Domain of Collagen XVIII Containing the Angiogenesis Inhibitor Endostatin," <u>EMBO Journal</u> , 17(15):4249-4256. | |
| | C213 | Sauve et al., (1991), "Localization in Human Interleukin 2 of the Binding Site to the α -chain (p55) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 88:4636-4640. | |
| | C214 | Schlom (1991), "Monoclonal Antibodies: They're More and Less Than You Think," in <u>Molecular Foundations of Oncology</u> , pp. 95-133. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|---|--|
| FORM PTO – 1449 INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO. LEX-023 APPLICANT(S): Gillies <i>et al.</i> SERIAL NO. 10/737,208 CONF. NO. 6855 FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C215 | Schnee et al., (1987), "Construction and Expression of a Recombinant Antibody-targeted Plasminogen Activator," <u>Proc. Natl. Acad. Sci. USA</u> , 84:6904-6908. | |
| | C216 | Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>J. Immunology</u> , 148(11):3433-3340. | |
| | C217 | Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of Controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93(16):1204-1214. | |
| | C218 | Senter et al., (1988), "Anti-tumor Effects of Antibody-alkaline Phosphatase Conjugates in Combination with Etoposide Phosphate," <u>Proc. Natl. Acad. Sci. USA</u> , 85(13):4842-4846. | |
| | C219 | Shanafelt et al., (2000), "A T-cell-Selective Interleukin 2 Mutein Exhibits Potent Antitumor Activity and is Well Tolerated <i>In Vivo</i> ," <u>Nature Biotechnology</u> , 18:1197-1202. | |
| | C220 | Sharma et al., (1999), "T cell-derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T cell and APC Function," <u>Journal of Immunology</u> , 163:5020-5028. | |
| | C221 | Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG Mediates Cytotoxicity by Human Monocytes That is Enhanced by Interferon- γ and is Not Blocked by Human IgG," <u>J. Immunology</u> , 137(11):3378-3382. | |
| | C222 | Shiff et al., (1995), "Sulindac Sulfide, an Aspirin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , 96:491-503. | |
| | C223 | Shin et al., (1990), "Expression and Characterization of an Antibody Binding Specificity Joined to Insulin-like Growth Factor 1: Potential Applications for Cellular Targeting," <u>Proc. Natl. Acad. Sci. USA</u> , 87:5322-5326. | |
| | C224 | Shinkawa et al., (2003), "The Absence of Fucose But Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473. | |
| | C225 | Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , 57:1329-1334. | |
| | C226 | Spiekermann et al., (2002), "Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <u>J. Exp. Med.</u> , 196:303-310. | |
| | C227 | Stevenson et al., (1997), "Conjugation of Human Fc γ in Closed-Hinge or Open-Hinge Configuration to Fab' γ and Analogous Ligands," <u>J. Immunology</u> , 158:2242-2250. | |
| | C228 | Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," Chapter 36, pp. 451-456, in <u>Therapeutic Immunology</u> , Austen et al., (eds.), Blackwell Science. | |
| | C229 | Sulitzeanu, (1993), "Immunosuppressive Factors in Human Cancer," pp. 247-266 in <u>Advances in Cancer Research</u> , Vol. 60, Vande Woude et al. (eds.), Academic Press, Inc. | |
| | C230 | Syed et al., (1998), "Efficiency of Signaling Through Cytokine Receptors Depends Critically on Receptor Orientation," <u>Nature</u> , 395:511-516. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|---|---|-----------------------|
| FORM PTO – 1449 | | ATTORNEY DOCKET NO. LEX-023 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | |
| | | SERIAL NO. 10/737,208 | CONF. NO. 6855 |
| | | FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C231 | Taniguchi et al., (1983), "Structure and Expression of a Cloned cDNA for Human Interleukin-2," <u>Nature</u> , 302:305-309. | |
| | C232 | Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>J. Immunology</u> , 143(8):2595-2601. | |
| | C233 | Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>J. Exp. Med.</u> , 178(2):661-667. | |
| | C234 | Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , 57:920-925. | |
| | C235 | <u>The Merck Manual of Diagnosis and Therapy</u> , 17 th Ed., (1999) pp. 990-993 and 1278-1283. | |
| | C236 | Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004. | |
| | C237 | Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , 48(5):1119-1123 | |
| | C238 | Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , 242:1166-1168 | |
| | C239 | Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , 84:4008-4027. | |
| | C240 | Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , 56:467-470. | |
| | C241 | Varki et al., (1984), "Antigens Associated with a Human Lung Adenocarcinoma Defined by Monoclonal Antibodies," <u>Cancer Research</u> , 44:681-687. | |
| | C242 | Verhoeyen et al., (1988), "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> , 239:1534-1536. | |
| | C243 | Villunger et al., (1997), "Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-induced Suppression of Immune Surveillance," <u>Blood</u> , 90(1):12-20. | |
| | C244 | Watanabe et al., (1997), "Long-term Depletion of Naive T cells in Patients Treated for Hodgkin's Disease," <u>Blood</u> , 90(9):3662-3672. | |
| | C245 | Weber et al., (2001), "Phase I Trial of huKS-IL2 Immunocytokine in Patients with Prostate Carcinoma: Clinical, PK, and Biological PD Results (Abstract)," <u>American Society of Clinical Oncology Program/Proceedings</u> , 20(Part 1):259a. | |
| | C246 | Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517. | |
| | C247 | Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82(5):1507-1516. | |
| | C248 | Wen et al., (1994), "Erythropoietin Structure-Function Relationships: Identification of Functionally Important Domains," <u>J. Biological Chemistry</u> , 269(36):22839-22846. | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|----------------------------------|--|--|----------------|
| FORM PTO – 1449 | | ATTORNEY DOCKET NO. LEX-023 | |
| INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | |
| | | SERIAL NO. 10/737,208 | CONF. NO. 6855 |
| | | FILING DATE: December 16, 2006 GROUP: 1653 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| | C249 | Williams et al., (1986), "Production of Antibody-tagged Enzymes by Myeloma Cells: Application to DNA Polymerase I Klenow Fragment," <u>Gene</u> , 43:319-324. | |
| | C250 | Williams et al., (1987), "Diphtheria Toxin Receptor Binding Domain Substitution with Interleukin-2: Genetic Construction and Properties of a Diphtheria Toxin-related Interleukin-2 Fusion Protein," <u>Protein Engineering</u> , 1(6):493-498. | |
| | C251 | Wooley et al., (1993), "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor Fc Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>J. Immunology</u> , 151:6602-6607. | |
| | C252 | Wu et al., (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," <u>Biochemical and Biophysical Research Communications</u> , 236:651-654. | |
| | C253 | Xiang et al., (1997), "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , 57:4948-4955. | |
| | C254 | Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925. | |
| | C255 | Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunology</u> , 163(7):3676-83. | |
| | C256 | Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer Induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J. Immunology</u> , 167(8):4560-5. | |
| | C257 | Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clinical Cancer Research</u> , 7(3 Supp):S856-S864. | |
| | C258 | Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269(5):3469-3474. | |
| | C259 | Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clinical Oncology</u> , 16(6):2169-80. | |
| | C260 | Zagozdzon et al., (1999), "Potentiation of Antitumor Effects of IL-12 in Combination with Paclitaxel in Murine Melanoma Model <i>In Vivo</i> ," <u>International Journal of Molecular Medicine</u> , 4:645-648. | |
| | C261 | Zheng et al., (1995), "Administration of Noncytolytic IL-10/Fc in Murine Models of Lipopolysaccharide-induced Septic Shock and Allogenic Islet Transplantation," <u>J. Immunology</u> , 154:5590-5600. | |
| EXAMINER | | DATE CONSIDERED | |

3061087